[Research progress on targeted delivery of proteasome inhibitor nanoparticles for the treatment of multiple myeloma].

Y X Lin, D H Jing, J Q Mi

Abstract readReviewEnglish Abstract

In one paragraph

Review in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Y X LinDepartment of Hematology, Ruijin Hospital, Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Shanghai 200025, China.

D H JingShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Shanghai 200025, China Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Shanghai 200025, China.

J Q MiDepartment of Hematology, Ruijin Hospital, Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Shanghai 200025, China Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Shanghai 200025, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, proteasome inhibitors have been widely applied in the treatment of multiple myeloma (MM), demonstrating significant therapeutic value. However, these drugs face numerous clinical challenges, such as short circulation half-life, poor water solubility, patient resistance, and severe adverse events. Nanoparticles for targeted drug delivery, with unique advantages, have shown promise as an effective solution to these issues. This paper reviews the mechanisms of nanotargeted drug delivery for proteasome inhibitors and the progress of their use in MM treatment both domestically and internationally, aiming to provide a reference for researchers in related fields.

Indexed as

Drug Delivery SystemsMultiple MyelomaNanoparticlesProteasome InhibitorsHumansProteasome Inhibitors

Identifiers

PMID41087190

DOI10.3760/cma.j.cn121090-20241201-00518

PMCPMC12541484

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.